Blog: MICROBOT MEDICAL INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

On November 15, 2022, Microbot Medical Inc. (the “Company”) issued a press
release announcing that it will be hosting a monthly educational webinar series,
the Access-Ability Live by MBOT, to focus on key issues impacting the future of
the endovascular space, including robotics and other medical devices that will
improve patient outcomes, and the place that the LIBERTY® Robotic System is
expected to play in it. Each month, the Company plans to partner with industry
leaders, such as physicians, hospital administrators, entrepreneurs, technicians
and financial experts for a live discussion and Q&A session to address
top-of-mind healthcare related topics.

The initial webinar will be held on November 16, 2022, at 1:00 pm ET, and hosted
by the Company’s Chief Medical Officer, Dr. Eyal Morag. Dr. Morag’s guest
speaker will be Dr. Sebastian Flacke, a global leader in the endovascular space
and Chief of Interventional Radiology and Director of non-invasive
Cardiovascular Imaging at Lahey Hospital & Medical Center. Dr. Flacke is
expected to address the current landscape for endovascular procedures, and how
it has changed over the past and the emerging technologies being developed today
that can potentially and significantly change how these procedures are going to
be performed in the near future. Dr. Flacke will also share his recent hands-on
experience with the LIBERTY Robotic System and the future impact that he
believes it will have on his practice once the system is cleared for
commercialization in the U.S.

To participate on the webinar, attendees need to register in advance at: After
registering, participants will receive a confirmation email containing
information about joining the webinar.

The press release, which is furnished as Exhibit 99.1 to this Current Report on
Form 8-K, is incorporated herein by reference. The information in this report
(including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not
be deemed to be “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section. This report will not be deemed an admission as to the materiality
of any information herein (including Exhibit 99.1).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Number    Description

99.1        Press Release dated November 15, 2022
104       Cover Page Interactive Data File (embedded within the Inline XBRL

© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s